WebDoctor Encyclopedia

Central nervous system

Papillary tumour of the pineal region

Papillary tumour of the pineal region is a rare brain tumour that grows near the pineal gland and often blocks the flow of brain fluid. Removing as much tumour as possible is the key treatment. It tends to come back locally, so regular MRI checks continue for years.

Medically reviewed Last reviewed November 15, 2026

What is a papillary tumour of the pineal region?

A papillary tumour of the pineal region (PTPR) is a rare brain tumour that grows in the pineal region, a small area deep in the centre of the brain. This area contains the pineal gland, the fluid channels that drain the brain and the upper part of the brainstem. Despite its location, PTPR does not seem to come from the pineal gland itself.

Researchers believe PTPR arises from a tiny, specialised structure nearby called the subcommissural organ. This structure is lined by cells similar to ependymal cells, the cells that line the brain’s fluid spaces (Fevre Montange et al., 2015). Under the microscope, the tumour forms finger-like projections (papillae), which gives it its name.

PTPR was first described as a separate tumour in 2003 and was added to the World Health Organization (WHO) classification of brain tumours in 2007. It is graded as WHO CNS grade 2 or 3. It mostly affects young and middle-aged adults, although children can also be affected.

The usual first symptoms come from hydrocephalus, a build-up of fluid caused by the tumour blocking fluid flow. Treatment is mainly surgery, often followed by radiotherapy. The tumour has a strong tendency to come back locally, so long-term follow-up is essential, but many people live for many years (Lancia et al., 2020).

1. Key facts at a glance

Feature Details
Type of tumour Neuroepithelial tumour with ependymal-like features, WHO CNS grade 2 or 3
Where it grows Pineal region, near the back of the third ventricle
Probable origin Subcommissural organ
Typical age Young adults; mean age about 33 years in pooled data
Sex Roughly equal in men and women
Main symptoms Headache and other signs of hydrocephalus
Main treatment Surgery, often with radiotherapy
Recurrence Common; more than half recur within 5 years
Outlook Most patients alive at 3 years; long-term survival is possible

2. Types

Molecular subtypes

A study of 76 tumours confirmed by DNA methylation profiling identified three molecular subtypes (Wu et al., 2024).

Subtype Features
PTPR-A One of the two main methylation groups
PTPR-B1 Frequent loss of chromosome 3 or 14
PTPR-B2 No such chromosome losses

Nearly half of the patients whose outcomes were examined had tumour progression, and the risk differed between subtypes. These subtypes may help predict behaviour in future, but are not yet used routinely to choose treatment.

Other tumours in the pineal region

Tumour How it differs
Pineocytoma Slow-growing tumour of the pineal gland itself
Pineal parenchymal tumour of intermediate differentiation Arises from pineal cells; KBTBD4 gene changes
Pineoblastoma Aggressive, mostly in children
Germ cell tumours Teenagers and young adults; tumour markers may be raised
Papillary ependymoma Similar features, but different location and genetics
Choroid plexus papilloma Papillary tumour of the fluid-producing tissue
Metastatic carcinoma Spread from cancer elsewhere, in older adults

Several of these can look similar under the microscope, so specialist pathology review is important (Fevre Montange et al., 2015).

Why grading is difficult

Exact rules for grading PTPR have not yet been fully defined (Fevre Montange et al., 2015). Pathologists look at how often the cells divide, whether there is dead tissue and how quickly the cells are growing, but these features do not always predict behaviour. This is one reason why research has turned to molecular subtypes, which may in future give a more reliable guide to the risk of recurrence.

3. Causes and risk factors

The cause of PTPR is unknown.

Factor Notes
Age Most common in the third and fourth decades
Sex No strong preference
Inherited conditions None known
Lifestyle or environment No known link
Genetic changes in the tumour Acquired changes, including chromosome losses; not inherited

4. How does it look

On scans

Feature Typical finding
Location Pineal region, at the back of the third ventricle
Borders Well-defined
Content Solid, often with cystic areas
MRI signal May show bright areas on T1 images before contrast
Contrast enhancement Usually present
Hydrocephalus Common

Under the microscope

Feature Description
Architecture Papillae with blood vessels at their core
Cells Column-shaped or cube-shaped cells in several layers
Pseudorosettes Cells arranged around blood vessels
Cytokeratin staining Strongly positive, especially cytokeratin 18
Electron microscopy Features of ependymal cells, such as many microvilli
Methylation profiling Confirms the diagnosis in difficult cases

5. Symptoms

Common symptoms

In pooled data, raised pressure in the head and hydrocephalus were the main clinical picture (Yamaki et al., 2019). Symptoms include:

  • Headache, often worse on waking
  • Nausea and vomiting
  • Blurred or double vision
  • Difficulty looking upwards
  • Unsteady walking

Less common symptoms

Symptom Possible cause
Drowsiness Severe hydrocephalus
Memory or concentration problems Raised pressure
Pupils that react poorly to light Pressure on the midbrain
Hormonal changes Rare effects on nearby structures
Back pain or leg symptoms Spread to the spine, which is uncommon

When to seek urgent help

Seek urgent medical attention for a sudden or severe headache with vomiting, drowsiness, confusion or sudden visual loss.

6. Diagnosis

Test Purpose
MRI of the brain with contrast Shows the tumour and fluid blockage
MRI of the spine Checks for spread
Tumour markers in blood and spinal fluid Help exclude germ cell tumours
Endoscopic biopsy Can be combined with treatment of hydrocephalus
Surgical removal Provides the full tumour for diagnosis
Specialist pathology review Distinguishes PTPR from similar tumours
DNA methylation profiling Confirms the diagnosis and subtype

Treatment of hydrocephalus

Procedure Notes
Endoscopic third ventriculostomy Creates a bypass for fluid; allows a biopsy
Shunt Drains fluid to the abdomen
Temporary external drain Used in emergencies

7. Treatment

There is no standard treatment proven by trials. Plans are based on pooled case reports and series and on expert consensus (Liu et al., 2024).

Surgery

Aspect Details
Aim Remove as much tumour as safely possible
How often performed About 82% of patients in pooled data
Complete removal achieved In about 71% of those operated
Effect on survival Having surgery was linked with better 3-year survival (Yamaki et al., 2019)

Interestingly, the same analysis did not show a clear additional survival benefit from complete removal compared with partial removal. Even so, most surgeons aim for the safest maximal removal.

Radiotherapy

Aspect Details
How often used About 72% of patients in a review of published cases
Conventional dose Between 45 Gy and 60 Gy in daily fractions
Stereotactic radiosurgery dose Between 12 Gy and 36 Gy
Side effects Treatment-related toxicity was very limited in the review

Because PTPR is considered a grade 2 or 3 tumour, reviewers suggested a higher total dose after surgery (Lancia et al., 2020). Radiotherapy is also used for recurrent tumours.

Chemotherapy

Chemotherapy has a limited, uncertain role. It may be considered for tumours that keep returning or spread, usually in a clinical trial or after specialist discussion.

Treatment by situation

Situation Typical approach
Newly diagnosed, removable Surgery, then focal radiotherapy in many cases
Small residual tumour Focal radiotherapy or radiosurgery
Local recurrence Further surgery, radiotherapy or radiosurgery
Spread along the spine Radiotherapy to affected areas; chemotherapy considered

What a treatment journey may look like

Step What happens Typical timing
Emergency care Treatment of hydrocephalus, steroids for swelling First days
Planning Specialist MRI, tumour markers, multidisciplinary meeting 1-2 weeks
Surgery Removal through the back of the head Within weeks
Pathology results Microscope, staining and molecular tests 2-4 weeks after surgery
Radiotherapy Daily weekday sessions About 5-6 weeks, starting 4-8 weeks after surgery
Rehabilitation Eye, balance and fatigue support Months

PTPR in children

PTPR is less common in children than in adults. Paediatric teams aim to limit radiotherapy where possible, because of its effects on the developing brain, growth and hormones. Children often need support with schooling and learning after treatment, and long-term follow-up continues into adulthood.

Side effects

Treatment Possible side effects
Surgery Double vision, upward-gaze problems, balance difficulties, bleeding, infection
Radiotherapy Tiredness, hair loss in the treated area, memory changes, hormone problems
Radiosurgery Swelling around the treated area, headache
Shunt Blockage or infection, requiring revision

8. Outlook (prognosis)

Measure Result
3-year survival (pooled data) About 84%
Local recurrence by 5 years About 60%
Local recurrence by 10 years More than 80%
Expected 10-year overall survival About 73%
Median time to recurrence About 29 months

These figures come from Yamaki et al. (2019) and Lancia et al. (2020). In the pooled analysis, larger tumour size was linked with poorer survival, while having surgery was linked with better survival.

Good functional outcomes

About six in ten patients in the pooled analysis had a good functional outcome, able to live independently (Yamaki et al., 2019). Recurrence does not always mean a poor result, because repeat surgery and radiotherapy can often control it.

9. Follow-up

Time Typical checks
First 2 years Brain MRI every 3-6 months
Years 3-5 MRI every 6 months
After 5 years Yearly MRI, continuing long term
Spine MRI If symptoms or brain findings suggest spread
Other checks Eye, hormone and memory assessments

Follow-up is lifelong in many cases, because recurrence can occur late.

10. Living with a papillary tumour of the pineal region

  • Keep all scan appointments, even when you feel well
  • Know the signs of shunt problems, such as headache, vomiting and drowsiness
  • Get help for vision problems from an orthoptist or eye specialist
  • Return to activities gradually, and ask about a phased return to work
  • Check driving rules with your doctor before driving
  • Keep a symptom diary to share with your team at follow-up visits
  • Seek support from brain tumour charities and counselling services

Living with a shunt

Topic Advice
Warning signs of blockage Headache, vomiting, drowsiness, blurred vision; seek help urgently
Signs of infection Fever, redness along the tubing, abdominal pain
Programmable valves Strong magnets, including some MRI scanners, can change settings; tell staff you have one
Activities Most normal activities are possible; ask about contact sports
Travel Carry details of your shunt and your neurosurgical centre

11. Frequently asked questions

Question Answer
Is it cancer? It is a grade 2 or 3 brain tumour that can recur, but it rarely spreads outside the brain and spine
Is it a tumour of the pineal gland? No; it grows next to the gland, probably from the subcommissural organ
Why does it come back so often? Its location makes complete removal difficult, and cells can remain
Will I need radiotherapy? Many people do, especially after partial removal
Can a recurrence be treated? Yes, with further surgery or radiotherapy in many cases
Is it inherited? No
Will I need a shunt? Only if fluid blockage cannot be relieved by other means
How long will follow-up last? Usually many years, often for life
Can I have children after treatment? Usually yes; ask about hormone checks if radiotherapy affected the pituitary region

12. Questions to ask your care team

  • Has the diagnosis been confirmed by a specialist neuropathologist?
  • Was methylation testing done?
  • How much of the tumour was removed?
  • Do you recommend radiotherapy now or only if it grows?
  • What are the signs of recurrence I should watch for?
  • How often will I have scans?
  • Who should I contact if I develop new headaches?
  • What rehabilitation services are available?

Resources

  1. Fevre Montange, M. et al. (2015) ‘Papillary tumor of the pineal region: histopathological characterization and review of the literature’, Neurochirurgie, 61(2-3), pp. 138-142.
  2. Lancia, A. et al. (2020) ‘Radiotherapy for papillary tumor of the pineal region: a systematic review of the literature’, Clinical Neurology and Neurosurgery, 190, 105646.
  3. Liu, A.P.Y. et al. (2024) ‘SNO-EANO-EURACAN consensus on management of pineal parenchymal tumors’, Neuro-Oncology, 26(12), pp. 2159-2173.
  4. Wu, Z. et al. (2024) ‘Papillary tumor of the pineal region: analysis of DNA methylation profiles and clinical outcomes in 76 cases’, Acta Neuropathologica Communications, 12(1), 117.
  5. Yamaki, V.N. et al. (2019) ‘Papillary tumor of the pineal region: systematic review and analysis of prognostic factors’, Neurosurgery, 85(3), pp. E420-E429.
  6. National Cancer Institute (2026) Adult Central Nervous System Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.